Researchers Identified Pathway Driving Colorectal Cancer
A study revealed that the VASH2 molecule promotes cancer progression and hinders chemotherapy effectiveness.
Updated on Sept. 24, 2026 in Cancer
Scientists have identified a molecular mechanism where VASH2 drives colorectal cancer progression by promoting alpha-tubulin detyrosination. This process prevents the degradation of YAP proteins, fueling tumor growth and creating resistance to chemotherapy.
Why it matters
Understanding how VASH2 and HDAC10 interact to sustain tumor growth offers a potential new target for therapeutic intervention. Inhibiting this specific pathway could restore chemosensitivity in patients who currently face poor treatment outcomes.
Researchers observed that VASH2 is upregulated in colorectal cancer tissues. The study demonstrated that VASH2 knockdown increases chemosensitivity in cancer cell lines, while HDAC10 stabilizes VASH2 by preventing its proteasomal degradation.
The players
VASH2
This molecule is upregulated in colorectal cancer and acts as a driver for disease progression and chemoresistance.
HDAC10
This enzyme stabilizes VASH2 protein levels by preventing its proteasomal degradation within cancer cells.
YAP
This protein serves as a key driver of cancer cell progression when its degradation is inhibited by the VASH2 pathway.
The details
The research highlights that VASH2 promotes alpha-tubulin detyrosination, which stabilizes YAP protein levels by reducing their phosphorylation and degradation. Simultaneously, HDAC10 functions to maintain higher VASH2 levels, effectively creating a protective environment for malignant cells.
Timeline
The research findings were published on September 24, 2026.
Deeper Dive
This study extends current research into the YAP-TEAD transcriptional pathway by uncovering how the VASH2-HDAC10 axis specifically prevents YAP degradation in colorectal cancers.
This discovery identifies a new biological target that could eventually lead to improved chemotherapy regimens for patients with colorectal cancer. By addressing chemoresistance, clinicians may one day be able to customize treatments to better overcome tumor-level defenses.
The takeaway
The study suggests that targeting the stabilization of VASH2 could be a vital strategy for mitigating chemoresistance. Researchers should prioritize investigating whether inhibiting HDAC10 can effectively reduce YAP levels and halt malignant growth in clinical settings.
Further reading
Learn more about the latest research in this field by visiting the Cancer section.
Source note: This article includes information reported by Nature.
